Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956957 | 0.83 | CYP3A4 (0.54) | ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL30231 | 0.83 | CYP3A4 (0.54) | ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL121851 | 0.83 | TSHR (0.46) | ALDH1A1KDM4ETSHR | |
| SCHEMBL29789730 | 0.80 | NPC1 (0.45) | ENPP2ALDH1A1TSHR | |
| SCHEMBL8475 | 0.80 | NPC1 (0.45) | ENPP2ALDH1A1TSHR | |
| SCHEMBL30414006 | 0.72 | CYP3A4 (0.68) | CYP3A4MAPK1 | |
| SCHEMBL4950024 | 0.72 | CYP3A4 (0.68) | CYP3A4MAPK1 | |
| SCHEMBL5710118 | 0.71 | CYP3A4 (0.54) | ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL19031988 | 0.69 | ENPP2 (0.38) | ENPP2CA2ALDH1A1CA1KDM4E | |
| SCHEMBL2662883 | 0.69 | ABL1 (0.33) | ENPP2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4026832-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | GENETECH, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | USP7, USP5, UBA7 | ENPP2 2104/4885CA2 4223/4885ALDH1A1 1201/4885 |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | USP7, USP5, UBA7 | ENPP2 2104/4885CA2 4223/4885ALDH1A1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.